EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

A One‐Strength Dose Escalation Regimen for Birch Pollen Subcutaneous Immunotherapy Is Safe and Tolerable in Children, Adolescents, and Adults

Marek Jutel iD, Ludger Klimek iD, Michael Gerstlauer iD, Dana Troyke, Kristina Duwensee, Christian Vogelberg iD

Allergy · 2026

DOI: 10.1111/all.70265 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2026. Verfasst von Marek Jutel und 5 weiteren Autor:innen. Beteiligte Einrichtung: All-MED Medical Research Institute, Wrocław, Poland. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Betula, Pollen, Allergens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Allergopharma GmbH & Co. KG, Reinbek, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergen immunotherapy is the only disease‐modifying treatment for IgE‐mediated diseases for patients 5 years and over. The question is often asked why children receive the same doses as adults. There is not a single dose‐finding study including children and/or adolescents. Moreover, randomized controlled trials that include all age groups but report effects separately are rare.

Method

This randomized trial investigated the safety and tolerability of an accelerated dose escalation schedule (One‐Strength group) compared to the standard regimen (Standard group) when using a birch pollen SCIT allergoid in patients aged 5–65 years.

Results

Overall, 201 patients were randomized to the two regimens: 87 adults, 52 adolescents, 62 children. Three hundred eighty‐two treatment‐related adverse drug reactions (ADRs) occurred in 81 patients (40.5%). A higher proportion of patients in the One‐Strength group (48.5%) experienced at least one ADR compared to those in the Standard group (32.0%). The majority of ADRs were local (93.3%), and the majority were of mild intensity (95.8%). 3 patients in the One‐Strength and 1 patient in the Standard group developed a total of 9 systemic ADRs, which all were classified as WAO grade 1 or 2 and most of mild intensity. No event of WAO grade 3 or higher was reported. No serious ADR occurred. Overall, tolerability was assessed as “very good” or “good” by more than 96% of investigators and patients. Safety and tolerability were comparable in the three age groups.

Conclusion

Birch pollen SCIT was safe and well‐tolerated when administered using a One‐Strength dose‐escalation regimen in patients aged 5–65 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicBetulaPollenAllergensRhinitis, Allergic, SeasonalHumansAdolescentChildChild, PreschoolAdultMiddle AgedFemaleMaleInjections, SubcutaneousAgedYoung AdultTreatment OutcomeImmunoglobulin E

Stichwörter der Autor:innen

One‐Strength dose escalationbirch pollenchildren and adultssafetysubcutaneous allergen immunotherapy

Substanzen

AllergensImmunoglobulin E

Autor:innen und Institutionen

  • All-MED Medical Research Institute, Wrocław, Poland.
  • Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland.
  • Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Pediatric and Adolescent Medicine, University Hospital Augsburg, Augsburg, Germany.
  • Allergopharma GmbH & Co. KG, Reinbek, Germany.
  • Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.

ORCID-Profile: Marek Jutel, Ludger Klimek, Michael Gerstlauer, Christian Vogelberg

Förderung

  • Allergopharma GmbH & Co. KG, Reinbek, Germany

Zitieren

APA

Jutel, M., Klimek, L., Gerstlauer, M., Troyke, D., Duwensee, K., & Vogelberg, C. (2026). A One‐Strength Dose Escalation Regimen for Birch Pollen Subcutaneous Immunotherapy Is Safe and Tolerable in Children, Adolescents, and Adults. Allergy. https://doi.org/10.1111/all.70265

Vancouver

Jutel M, Klimek L, Gerstlauer M, Troyke D, Duwensee K, Vogelberg C. A One‐Strength Dose Escalation Regimen for Birch Pollen Subcutaneous Immunotherapy Is Safe and Tolerable in Children, Adolescents, and Adults. Allergy. 2026. doi:10.1111/all.70265

BibTeX
@article{Jutel2026,
  author = {Jutel, Marek and Klimek, Ludger and Gerstlauer, Michael and Troyke, Dana and Duwensee, Kristina and Vogelberg, Christian},
  title = {A One‐Strength Dose Escalation Regimen for Birch Pollen Subcutaneous Immunotherapy Is Safe and Tolerable in Children, Adolescents, and Adults},
  journal = {Allergy},
  year = {2026},
  doi = {10.1111/all.70265}
}
Kostenlos starten →